Abeona Therapeutics Inc
PCJ
Company Profile
Business description
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Contact
6555 Carnegie Avenue
4th Floor
ClevelandOH44103
USAT: +1 646 813-4701
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
226
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
We’re expecting another beat-and-raise quarter, while watching the roadmap and discussions of its financing and partnership deals.
stocks
Wide moat airport share steps up its investments
Profits flatten as airport ramps up redevelopment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,316.70 | 9.20 | 0.10% |
| CAC 40 | 8,453.01 | 31.42 | -0.37% |
| DAX 40 | 26,106.60 | 29.96 | -0.11% |
| Dow JONES (US) | 53,400.34 | 123.33 | 0.23% |
| FTSE 100 | 10,854.32 | 37.76 | 0.35% |
| HKSE | 25,517.33 | 492.13 | -1.89% |
| NASDAQ | 26,076.88 | 103.57 | -0.40% |
| Nikkei 225 | 65,528.09 | 488.27 | -0.74% |
| NZX 50 Index | 13,881.88 | 90.78 | -0.65% |
| S&P 500 | 7,662.75 | 11.62 | -0.15% |
| S&P/ASX 200 | 9,103.10 | 9.90 | 0.11% |
| SSE Composite Index | 3,882.01 | 23.19 | -0.59% |